Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals is a biotechnology company that has a promising future due to its innovative Diffusphere technology which has shown strong potential in treating chronic conditions such as osteoarthritis and eosinophilic esophagitis. With a strong pipeline of drugs, including its lead product EP-104 which has shown promising results in clinical trials, the company is well-positioned for future success. Positive commentary and data from physicians and clinical trials, as well as the potential for expanding into new indications, make Eupraxia an attractive investment opportunity.

Bears say

Eupraxia Pharmaceuticals is facing significant challenges in gaining market acceptance for their products, with expensive, recurring treatments like mechanical dilation and short-acting steroids being the primary competitors for EoE and strictures, respectively. It will be crucial for the company to provide strong clinical data and demonstrate cost-effectiveness in order to compete with established treatments from larger companies and address potential financing and cross-border risks. With a high probability-weighted success rate for EP-104GI and a late 2028/early 2029 launch, the stock's valuation based on its DCF model is $183M, but as a negative sentiment towards competition, the 11.0% WACC shows claims that it may miss out on an appropriate timeframe in competition.

EPRX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 2 analysts, EPRX has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.